Grant to Be Used to Fund Ongoing Clinical Trials for Brain Cancer
DNAtrix Inc., a biotech company focusing on the development of oncolytic
viruses for cancer, announced today that it has been awarded a product
development grant for $10.8 million to fund the company’s clinical-stage
program in glioblastoma—the most aggressive type of brain cancer. The
grant from the Cancer Prevention and Research Institute of Texas (CPRIT)
is entitled “Clinical development and commercialization of oncolytic
adenovirus for treating malignant glioma.”
The grant awarded to DNAtrix will be used to drive the clinical
development of DNX-2401, the lead product candidate that is currently
undergoing a Phase Ib trial in combination with temozolomide for
recurrent glioblastoma. DNX-2401 uses a genetically modified adenovirus
that kills tumor cells selectively. In an earlier Phase I study in
recurrent glioblastoma, DNX-2401 demonstrated an excellent safety
profile and promising efficacy results.
The CPRIT grants support oncology-focused research and development
conducted by Texas-based companies and relocation of existing
oncology-focused companies to Texas. These grants cover a range of
product development sectors including therapeutics, devices and drug
development. After undergoing CPRIT’s review process, the grants were
recommended by their respective program review councils and approved by
the Oversight Committee.
“We are thrilled to receive this generous grant from the Cancer
Prevention and Research Institute of Texas, as these funds will
accelerate DNAtrix’s efforts to pursue the clinical development of our
lead oncolytic virus product for glioblastoma,” said Dr. Frank Tufaro,
Chief Executive Officer of DNAtrix. “We appreciate the support from such
a reputable organization as CPRIT, as it offers additional validation of
our cancer program and the clinical benefits that we continue to observe
in our clinical trials including long-term survival and tumor
Beginning operations in 2009, CPRIT provides funding for scientific
research, product development and prevention programs. Learn more at www.cprit.state.tx.us.
About DNAtrix Inc.
As a clinical-stage company developing modified oncolytic viruses for
the treatment of the most aggressive forms of cancer, DNAtrix is a
privately held company headquartered in Houston, Texas. For more
information, please visit the company website at http://www.dnatrix.com.
Michelle Chen, 650-690-6470
Source: DNAtrix Inc.